Mustang Bio Inc Stock News

Mustang Bio Inc (NASDAQ: MBIO) and the City of Hope, an independent cancer research and treatment center, have dosed the first patient in Phase 1 trial evaluating MB-101 in patients with leptomen

WORCESTER, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in

Fred Hutchinson Cancer Research Center to present updated interim data from ongoing MB-106 Phase 1/2 clinical trial Fred Hutchinson Cancer Research Center to present updated interim data from ongoing

The Phase 1/2 multicenter study to assess the safety, tolerability and efficacy of MB-106 in patients with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia is

NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell a

WORCESTER, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in

Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.

Mustang Bio (NASDAQ: MBIO) shares are trading higher after the company announced the FDA has lifted the clinical hold for its pivotal phase 2 MB-107 clinical trial. The company plans to enroll the fir

FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial

Penny stocks are cheap for a reason, as there are obvious flaws. However, with those flows comes opportunity.

WORCESTER, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying c

Data presented at the 62 nd American Society of Hematology (ASH) Annual Meeting show extremely favorable safety profile and clinical activity

Call to be held Wednesday, December 9, 2020, at 1:00 p.m. EST Call to be held Wednesday, December 9, 2020, at 1:00 p.m. EST

WORCESTER, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in